6 results on '"Biffoni, M"'
Search Results
2. The COVID-19 outbreak and de-escalation of thyroid cancer diagnosis and treatment.
- Author
-
Grani G, Ciotti L, Del Gatto V, Montesano T, Biffoni M, Giacomelli L, Sponziello M, Pecce V, Lucia P, Verrienti A, Filetti S, and Durante C
- Subjects
- Humans, Intensive Care Units, Disease Outbreaks, COVID-19, Thyroid Neoplasms diagnosis, Thyroid Neoplasms epidemiology, Thyroid Neoplasms therapy
- Published
- 2022
- Full Text
- View/download PDF
3. Ultrasonography scoring systems can rule out malignancy in cytologically indeterminate thyroid nodules.
- Author
-
Grani G, Lamartina L, Ascoli V, Bosco D, Nardi F, D'Ambrosio F, Rubini A, Giacomelli L, Biffoni M, Filetti S, Durante C, and Cantisani V
- Subjects
- Adult, Aged, Diagnosis, Differential, Female, Humans, Male, Middle Aged, Predictive Value of Tests, Reproducibility of Results, Retrospective Studies, Sensitivity and Specificity, Thyroid Neoplasms pathology, Thyroid Nodule classification, Thyroid Nodule pathology, Tomography, X-Ray Computed, Thyroid Neoplasms diagnostic imaging, Thyroid Nodule diagnostic imaging, Ultrasonography methods
- Abstract
Purpose: To assess the accuracy and reproducibility of ultrasonography classification systems in characterizing cytologically indeterminate thyroid nodules., Methods: We retrospectively identified 49 nodules that had been surgically resected owing to features classified as indeterminate according to 2010 Italian Consensus on Thyroid Cytology criteria. Three experienced sonographers independently reviewed original sonographic images of each nodule and classified it using the 2015 American Thyroid Association (ATA) guidelines and the Thyroid Imaging Reporting and Data System (TI-RADS) classification proposed by Korean radiologists; later, images were reviewed jointly to obtain consensus classifications of each nodule. Original cytology slides were similarly reviewed by three experienced cytopathologists, who reclassified the nodule (independently, then jointly) according to revised Italian Consensus on Thyroid Cytology (ICTC-2014) criteria. Consensus ICTC-2014, ATA, and TI-RADS classifications were analyzed against surgical histology reports to estimate each system's sensitivity, specificity, positive and negative predictive values., Results: Of the 49 indeterminate nodules examined, 30 (61.2 %) were histologically benign. Consensus ICTC-2014 classification correctly classified malignant nodules with positive predictive value of 50 % and negative predictive value of 90 %. Sonographic classification of nodules as intermediate to high suspicion by ATA or TI-RADS category 4c displayed positive predictive value of 63 and 71 %, respectively; positive predictive values dropped to 44 and 42 % when lower positivity thresholds were used (ATA low suspicion, TI-RADS category 4a). Negative predictive values for ATA and TI-RADS were 91 and 74 %, respectively, with higher positivity thresholds and 100 % for both with lower thresholds. All systems displayed appreciable inter-observer variability (Krippendorff alphas: ATA 0.36, TIRADS 0.42, ICTC-2014 0.74)., Conclusions: With stringent negativity cut-offs, American Thyroid Association and Thyroid Imaging Reporting and Data System assessment of cytologically indeterminate thyroid nodules allows high-confidence exclusion of malignancy.
- Published
- 2017
- Full Text
- View/download PDF
4. The true cost of thyroid surgery determined by a micro-costing approach.
- Author
-
Filetti S, Ladenson PW, Biffoni M, D'Ambrosio MG, Giacomelli L, and Lopatriello S
- Subjects
- Costs and Cost Analysis, Humans, Italy, Reimbursement Mechanisms, Health Care Costs, Hospital Costs, Hospitalization economics, Thyroid Gland surgery, Thyroidectomy economics
- Abstract
Whether the amount of the current DRG tariff for thyroid surgery covers its actual cost has been questioned. We estimated a reliable cost of thyroid surgery for a large Italian hospital. A micro-costing approach is used with data from the University Hospital "Umberto I," a large facility that conducts a high volume of thyroidectomy surgical procedures in the Lazio region. The direct costs of surgery and hospitalization for a total and a hemi-thyroidectomy were €4956 and €4673, respectively. When compared to the DRG tariff of €3340, total thyroidectomy was €1616 (48 %) more per procedure and hemi-thyroidectomy was €1333 (40 %) more per procedure. This DRG shortfall is calculated to generate an annual procedure-specific deficit of approximately €1.38 million for this hospital. Furthermore, when the costs associated with pre-surgical work-up, post-surgical follow-up, and complications management through 12 months are incorporated, the estimated costs of total and hemi-thyroidectomy rose to €5812 and €5277, respectively. The true cost of thyroid surgery in Italy is significantly higher than what has been reported in the literature or reimbursed by the DRG tariff.
- Published
- 2017
- Full Text
- View/download PDF
5. Papillary thyroid carcinomas with biochemical incomplete or indeterminate responses to initial treatment: repeat stimulated thyroglobulin assay to identify disease-free patients.
- Author
-
Lamartina L, Montesano T, Trulli F, Attard M, Torlontano M, Bruno R, Meringolo D, Monzani F, Tumino S, Ronga G, Maranghi M, Biffoni M, Filetti S, and Durante C
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Autoantibodies blood, Carcinoma, Papillary surgery, Female, Humans, Male, Middle Aged, Neoplasm Recurrence, Local blood, Retrospective Studies, Thyroid Neoplasms surgery, Treatment Outcome, Young Adult, Carcinoma, Papillary blood, Neoplasm Recurrence, Local diagnosis, Thyroglobulin blood, Thyroid Neoplasms blood, Thyroidectomy
- Abstract
Papillary thyroid cancer (PTC) patients treated with thyroidectomy and radioiodine remnant ablation (RRA) often have detectable TSH-stimulated thyroglobulin (Tg) levels without localizable disease after primary treatment. To assess the value of repeat stimulated Tg assays in these patients' follow-up, we retrospectively analyzed 86 cases followed in 5 Italian thyroid-cancer referral centers. We enrolled 86 patients with PTCs treated with total/near-total thyroidectomy plus RRA between January 1,1990 and January 31, 2006. In all cases, the initial postoperative visit revealed stimulated serum Tg ≥1 ng/mL, negative Tg antibodies, and no structural evidence of disease. None received empiric radioiodine therapy. Follow-up (median: 9.6 years) included neck ultrasound and basal Tg assays (yearly) and at least 1 repeat stimulated Tg assay. Of the 86 patients analyzed (initial risk: low 63 %, intermediate 35 %, high 2 %), one (1 %) had ultrasound-detected lymph node disease and persistently elevated stimulated Tg levels at 3 years. In 17 (20 %), imaging findings were consistently negative, but the final stimulated Tg levels was still >1 ng/mL (median 2.07 ng/mL, range 1.02-4.7). The other 68 (80 %) appeared disease-free (persistently negative imaging findings with stimulated Tg levels ≤1 ng/mL). Mean intervals between first and final stimulated Tg assays were similar (5.2 and 4.8 years) in subgroups with versus without Tg normalization. Reclassification as disease-free was significantly more common when initial stimulated Tg levels were indeterminate (<10 ng/mL). In unselected PTC cohorts with incomplete/indeterminate biochemical responses to thyroidectomy and RRA, periodic remeasurement of stimulated Tg allows most patients to be classified as disease-free.
- Published
- 2016
- Full Text
- View/download PDF
6. Molecular profiles of cancer stem-like cell populations in aggressive thyroid cancers.
- Author
-
Dima M, Pecce V, Biffoni M, Di Gioia CR, Tallini G, Biffoni M, Rosignolo F, Verrienti A, Sponziello M, Damante G, Russo D, and Durante C
- Subjects
- Aldehyde Dehydrogenase metabolism, Cell Line, Tumor, Cell Proliferation drug effects, Crizotinib, Humans, Phosphorylation drug effects, Pyrazoles pharmacology, Pyridines pharmacology, Thyroid Gland drug effects, Thyroid Gland pathology, Thyroid Neoplasms pathology, Biomarkers, Tumor metabolism, Neoplastic Stem Cells, Thyroid Gland metabolism, Thyroid Neoplasms metabolism
- Abstract
A substantial proportion of patients with advanced thyroid carcinoma fail to respond to or at some point become refractory to conventional therapies. This resistance and the phenomena of thyroid cancer progression and metastasis themselves are thought to be related to tumor-cell sub-populations with stem-like properties. We isolated thyrospheres from four advanced thyroid carcinomas that were resistant to radioiodine therapy and analyzed their molecular profiles. ALDH activity and proteomic profile of main stem cell markers were used to assess stem cell properties. The TaqMan Low Density Array approach was used to evaluate the expression of several genes involved in the EMT process. The phosphorylation status of tyrosine kinase receptors (RTKs) was analyzed to identify potential markers for targeted therapies. We then investigated the effects of the EMT-inhibitor crizotinib on both cell proliferation and phosphorylation status of RTK targets. The cancer stem-like properties of a subset of cells from primary cultures of each tumor were demonstrated. A wide variability among thyrospheres arising from the four thyroid cancers in terms of ALDH activity, stem cell marker expression, and phosphoproteome profiling was present. Dysregulated expression of genes involved in the EMT was observed in all four thyrosphere lines. Treatment with crizotinib was ineffective in cancer stem-like cells, suggesting the presence of a mechanism of resistance in thyrospheres. Collectively, our data indicate that thyroid cancer stem-like populations vary markedly from tumor to tumor and require detailed molecular and biological characterization if they are to be used as the basis of "personalized" treatment of aggressive disease.
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.